TLDR: EVERSANA has launched the EVERSANA AI Accelerator, a dedicated center of excellence aimed at transforming life sciences commercialization through advanced AI research, services, and solutions. This initiative seeks to integrate AI across the pharmaceutical value chain, from drug pricing to patient adherence, leveraging strategic partnerships and proprietary technologies.
CHICAGO – July 15, 2025 – EVERSANA®, a leading global provider of commercialization services to the life sciences industry, today announced the launch of the EVERSANA AI Accelerator. This new dedicated center of excellence (COE) is designed to fundamentally transform life sciences commercialization by harnessing the power of artificial intelligence.
Under the leadership of Faruk Capan, EVERSANA’s Chief Innovation Officer, the EVERSANA AI Accelerator is set to reimagine every stage of life sciences commercialization. This will be achieved through cutting-edge AI research, comprehensive transformation services, and the development of innovative solutions. Jim Lang, Chief Executive Officer of EVERSANA, emphasized the significance of this initiative, stating, “Faruk and team have created the space where AI innovation in our complex sector is born. Not only is it transforming every facet of our operation, but it is also creating a healthier world.” Lang further added, “Frankly, patients have waited far too long to reap the benefits of what’s possible when pharma commercialization is propelled by AI.”
The launch comes as the McKinsey Global Institute (MGI) estimates that generative AI could generate an annual value of $60 billion to $110 billion across the entire pharmaceutical value chain, with a significant portion—$18 billion to $30 billion—attributed to commercialization alone.
The EVERSANA AI Accelerator’s core components include:
Dedicated AI and Commercialization Expertise: Bringing together AI innovators and life sciences leaders to address challenges in global drug pricing, promotion, access, reimbursement, adherence, and product delivery.
Formidable Technology Partnerships: Collaborating with industry-leading technology companies such as Amazon Web Services, Google, Salesforce, Veeva, and Modus Create to ‘pharmatize’ AI with solutions tailored for real-world life sciences challenges.
Forward-Thinking Pharmaceutical Companies: Engaging pharmaceutical and medical device companies, as well as start-ups, that are actively deploying or piloting new AI platforms and toolsets.
Breakthrough Technology Deployments: Focusing on the development and integration of proprietary and third-party technologies into the AI-activated EVERSANA ORCHESTRATE™ Operating System, ensuring efficient and effective end-to-end commercialization.
Recent advancements from the EVERSANA AI Accelerator include EVERSANA ORCHESTRATE MLR, an AI-powered Medical, Legal & Regulatory platform that recently received an Emerald Pinnacle Technology Award. The Accelerator’s R&D pipeline is currently beta-testing further advancements in pharmaceutical marketing, patient hub services, and broader end-to-end commercialization operations.
Also Read:
- Indegene Unveils NEXT Medical Writing Automation Platform, Revolutionizing Life Sciences Documentation with Generative AI
- Clinical Research Leaders Establish Council for Ethical AI Oversight
Lang highlighted EVERSANA’s long-standing commitment to innovation: “Innovation isn’t new to EVERSANA. From our COMPLETE Commercialization model to the use of agentic KOL influencers, evolution is in our DNA. Today, we give that spirit of transformation a home in our global enterprise.” EVERSANA serves over 650 organizations, including innovative start-ups and established pharmaceutical companies, with the goal of advancing life sciences solutions for a healthier world.
